M&A Deal Summary

Astellas Pharma Acquires Ogeda SA

On April 3, 2017, Astellas Pharma acquired life science company Ogeda SA for 500M EUR

Acquisition Highlights
  • This is Astellas Pharma’s 5th transaction in the Life Science sector.
  • This is Astellas Pharma’s 4th largest (disclosed) transaction.
  • This is Astellas Pharma’s 1st transaction in Belgium.

M&A Deal Summary
Date 2017-04-03
Target Ogeda SA
Sector Life Science
Buyer(s) Astellas Pharma
Deal Type Add-on Acquisition
Deal Value 500M EUR
Advisor(s) White & Case (Legal)

Target

Ogeda SA

Gosselies, Belgium
Ogeda SA is a clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women's health disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Astellas Pharma

Tokyo, Japan
Category Company
Founded 1923
Sector Life Science
Employees14,754
Revenue 1.60T JPY (2024)
DESCRIPTION
Astellas office complex in Northbrook, Illinois.
Astellas office complex in Northbrook, Illinois.

Astellas Pharma is a pharmaceutical company committed to the therapeutic fields of urology, immunology, oncology, neuroscience and DM complications and metabolic diseases. Astellas Pharma was incorporated in 1923 and is based in Tokyo, Japan.

DEAL STATS #
Overall 5 of 14
Sector (Life Science) 5 of 13
Type (Add-on Acquisition) 5 of 14
Country (Belgium) 1 of 1
Year (2017) 1 of 2
Size (of disclosed) 4 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-03-28 Astellas Pharma - 16 Long-Listed Products

Chuo-Ku, Japan

Astellas Pharma, Inc. - 16 Long-Listed Products is a provider of medical products in Chuo-Ku, Japan.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-12-01 Mitobridge

Cambridge, Massachusetts, United States

Mitobridge, Inc. is a developer of small molecule therapeutics that enhance mitochondrial function and that build upon the emerging scientific findings linking mitochondrial dysfunction with disease pathologies. Mitobridge was founded in 2011 and is based in Cambridge, Massachusetts.

Buy $166M
Mergr

Product

Company

Legal